Notice of Results

Arix Bioscience PLC (ARIX) Notice of Results 21-Jul-2021 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Arix Bioscience plc Notice of Results LONDON, 21 July 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, will announce its interim results for the six months ended 30 June 2021, on Thursday 12 August 2021. [ENDS] Enquiries For more information on Arix, please contact: Arix Bioscience plc Charlotte Parry, Head of Investor Relations [phone] [e-mail] Optimum Strategic Communications Mary Clark, Manel Mateus [phone] [e-mail] About Arix Bioscience plc Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

ISIN:	GB00BD045071
Category Code:	NOR
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
OAM Categories:	3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:	118082
EQS News ID:	1220491

End of Announcement	EQS News Service